DK1396539T3 - Anti-blodkoagulationsfaktor VIII-antistof af den humane type - Google Patents
Anti-blodkoagulationsfaktor VIII-antistof af den humane typeInfo
- Publication number
- DK1396539T3 DK1396539T3 DK02738656T DK02738656T DK1396539T3 DK 1396539 T3 DK1396539 T3 DK 1396539T3 DK 02738656 T DK02738656 T DK 02738656T DK 02738656 T DK02738656 T DK 02738656T DK 1396539 T3 DK1396539 T3 DK 1396539T3
- Authority
- DK
- Denmark
- Prior art keywords
- fviii
- factor viii
- human
- blood coagulation
- coagulation factor
- Prior art date
Links
- 108010054218 Factor VIII Proteins 0.000 title abstract 2
- 102000001690 Factor VIII Human genes 0.000 title abstract 2
- 239000003114 blood coagulation factor Substances 0.000 title 1
- 229940019700 blood coagulation factors Drugs 0.000 title 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 7
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 5
- 102000057593 human F8 Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000007790 solid phase Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001177640 | 2001-06-12 | ||
| PCT/JP2002/005783 WO2002101040A1 (en) | 2001-06-12 | 2002-06-11 | Human-type anti-blood coagulation factor viii antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1396539T3 true DK1396539T3 (da) | 2009-02-09 |
Family
ID=19018448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02738656T DK1396539T3 (da) | 2001-06-12 | 2002-06-11 | Anti-blodkoagulationsfaktor VIII-antistof af den humane type |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7214785B2 (da) |
| EP (1) | EP1396539B1 (da) |
| JP (1) | JP4205576B2 (da) |
| KR (1) | KR100925348B1 (da) |
| AT (1) | ATE415472T1 (da) |
| AU (1) | AU2002313194B9 (da) |
| CA (1) | CA2418808A1 (da) |
| DE (1) | DE60230037D1 (da) |
| DK (1) | DK1396539T3 (da) |
| ES (1) | ES2316574T3 (da) |
| PT (1) | PT1396539E (da) |
| WO (1) | WO2002101040A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7829085B2 (en) * | 1999-07-14 | 2010-11-09 | Life Sciences Research Partners Vzw | Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII |
| EP1706079B1 (en) | 2003-08-14 | 2013-02-20 | ThromboGenics N.V. | Antibodies against factor viii with modified glycosylation in the variable region |
| CA2616902A1 (en) | 2005-07-29 | 2007-02-15 | Life Sciences Research Partners Vzw | Human inhibitory anti-factor viii antibodies binding to the a2 domain |
| EP2333555A1 (de) | 2009-12-09 | 2011-06-15 | Siemens Healthcare Diagnostics Products GmbH | Heterogener Gerinnungstest |
| WO2014075205A1 (zh) * | 2012-11-15 | 2014-05-22 | Cai Shenghe | 一种凝血八因子及其变异体纯化方法 |
| US11090373B2 (en) * | 2015-12-04 | 2021-08-17 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Antigen-specific T cells for inducing immune tolerance |
| WO2018111010A1 (ko) * | 2016-12-14 | 2018-06-21 | (주) 팬젠 | 항-혈액응고 제viii인자 항체 및 그 용도 |
| CN110382547B (zh) * | 2016-12-14 | 2023-06-06 | 盼展生物技术有限公司 | 抗凝血因子viii抗体及其用途 |
| CN108409863B (zh) * | 2017-02-10 | 2023-09-26 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2838166B2 (ja) | 1989-11-10 | 1998-12-16 | バクスター、インターナショナル、インコーポレイテッド | 第▲ｖｉｉｉ▼因子阻害剤産生の抑制のための医薬組成物および方法 |
| MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| DE60033814T2 (de) | 1999-07-14 | 2007-11-08 | D. Collen Research Foundation Vzw | Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers |
| JP4656478B2 (ja) | 2000-02-22 | 2011-03-23 | 株式会社医学生物学研究所 | 抗体ライブラリー |
-
2002
- 2002-06-11 PT PT02738656T patent/PT1396539E/pt unknown
- 2002-06-11 AT AT02738656T patent/ATE415472T1/de not_active IP Right Cessation
- 2002-06-11 AU AU2002313194A patent/AU2002313194B9/en not_active Ceased
- 2002-06-11 DK DK02738656T patent/DK1396539T3/da active
- 2002-06-11 US US10/344,514 patent/US7214785B2/en not_active Expired - Fee Related
- 2002-06-11 WO PCT/JP2002/005783 patent/WO2002101040A1/ja active Application Filing
- 2002-06-11 EP EP02738656A patent/EP1396539B1/en not_active Expired - Lifetime
- 2002-06-11 JP JP2003503790A patent/JP4205576B2/ja not_active Expired - Fee Related
- 2002-06-11 ES ES02738656T patent/ES2316574T3/es not_active Expired - Lifetime
- 2002-06-11 DE DE60230037T patent/DE60230037D1/de not_active Expired - Lifetime
- 2002-06-11 KR KR1020037001948A patent/KR100925348B1/ko not_active Expired - Fee Related
- 2002-06-11 CA CA002418808A patent/CA2418808A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002313194B2 (en) | 2007-12-13 |
| JPWO2002101040A1 (ja) | 2004-09-24 |
| ES2316574T3 (es) | 2009-04-16 |
| JP4205576B2 (ja) | 2009-01-07 |
| US7214785B2 (en) | 2007-05-08 |
| EP1396539A4 (en) | 2004-07-28 |
| EP1396539A1 (en) | 2004-03-10 |
| WO2002101040A1 (en) | 2002-12-19 |
| KR100925348B1 (ko) | 2009-11-09 |
| AU2002313194B9 (en) | 2008-06-05 |
| ATE415472T1 (de) | 2008-12-15 |
| KR20030029128A (ko) | 2003-04-11 |
| CA2418808A1 (en) | 2002-12-19 |
| US20040120951A1 (en) | 2004-06-24 |
| DE60230037D1 (de) | 2009-01-08 |
| AU2002313194B8 (en) | 2002-12-23 |
| EP1396539B1 (en) | 2008-11-26 |
| PT1396539E (pt) | 2009-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| CY1121451T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα κατα του ctla-4 | |
| CY1116167T1 (el) | Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1 | |
| DE69839270D1 (de) | Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen | |
| ATE476994T1 (de) | Antikörper gegen gpnmb und ihre verwendungen | |
| CY1107708T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης | |
| HRP20090527T1 (en) | Nogo-a neutralising immunoglobulins for treatment of neurological diseases | |
| ATE414718T1 (de) | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften | |
| DK1396539T3 (da) | Anti-blodkoagulationsfaktor VIII-antistof af den humane type | |
| CA2469833A1 (en) | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them | |
| HUS1600041I1 (hu) | VII-es véralvadási faktor-FC kiméra proteinek hemosztázis rendellenesség kezelésére | |
| ATE341563T1 (de) | Humanisierte antikörper gegen das respiratorische syncytialvirus | |
| HK1070907A1 (en) | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same | |
| RS51468B (en) | COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137) | |
| TNSN04078A1 (fr) | Antibodies to cd40 | |
| CY1110033T1 (el) | Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45 | |
| ATE517926T1 (de) | Antikörper zur hemmung der aktivität von mmp-2 und mmp-9 | |
| WO2003048194A3 (de) | Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie | |
| DE50015629D1 (de) | Verwendung cd28 spezifischer monoklonaler antikörpsetzung zur behandlung von virusinfektionen | |
| ATE490983T1 (de) | Humane antikörper gegen das humane glycoprotein vi und deren verwendung | |
| EP1411962A4 (en) | TREATMENT OF PANCREATIC CANCER WITH A MONOCLONAL ANTIBODY | |
| Welschof et al. | The antigen binding domain of non-idiotypic human anti-F (ab′) 2 autoantibodies: study of their interaction with IgG hinge region epitopes | |
| TNSN02089A1 (fr) | Anticorps a cd40 | |
| TH42174A3 (th) | แอนติบอดีที่ทำให้เหมือนมนุษย์ซึ่งจำเพาะสำหรับ 4-1bb ของมนุษย์และสารผสมทางเภสัชกรรม ซึ่งประกอบด้วยสิ่งเดียวกัน | |
| JP2006502739A5 (da) |